Dermatophagoides Pteronyssinus

This article explores clinical trials investigating the use of Dermatophagoides Pteronyssinus (house dust mite) extract in the treatment of allergic rhinitis. These studies aim to assess the safety, efficacy, and immunological effects of allergen-specific immunotherapy using this extract. The trials focus on different aspects, including regulatory T cell responses, nasal provocation tests for diagnosis, and comparative evaluations of new immunotherapeutic agents.

Table of Contents

What is Dermatophagoides Pteronyssinus?

Dermatophagoides Pteronyssinus, often referred to as Der p, is a type of house dust mite. It’s not actually a medication itself, but rather an allergen extract used in immunotherapy treatments for allergies[1]. This extract is derived from the dust mite and is used to help patients build tolerance to the allergen, reducing their allergic reactions over time.

Conditions Treated

Dermatophagoides Pteronyssinus extract is primarily used to treat:

  • Allergic Rhinitis: This is a condition commonly known as hay fever, which causes symptoms like sneezing, runny nose, and itchy eyes when exposed to allergens like dust mites[1].
  • House Dust Mite Allergy: This is a specific type of allergy where the immune system overreacts to proteins found in dust mite droppings and body fragments[3].

These conditions can significantly impact a person’s quality of life, causing discomfort and interfering with daily activities.

How It Works

Dermatophagoides Pteronyssinus extract works through a process called allergen immunotherapy. Here’s how it functions:

  1. The extract contains small amounts of the allergen (dust mite proteins).
  2. When administered to patients, it gradually exposes their immune system to the allergen.
  3. Over time, this exposure helps the immune system build tolerance to the allergen.
  4. As a result, when the person encounters dust mites in their environment, their allergic reaction becomes less severe[1].

This treatment aims to modify the body’s immune response, potentially providing long-term relief from allergy symptoms.

Administration and Dosage

Dermatophagoides Pteronyssinus extract can be administered in different ways:

  • Subcutaneous Immunotherapy (SCIT): This involves injections under the skin, typically following a schedule that starts with a low dose and gradually increases[1].
  • Nasal Provocation Test: In some cases, the extract may be administered as a nasal spray. This method is often used for diagnostic purposes or as part of a treatment regimen[2].

The dosage and administration schedule can vary depending on the specific treatment plan and the patient’s response. It’s crucial to follow the healthcare provider’s instructions carefully.

Effectiveness

Clinical trials have shown promising results for the effectiveness of Dermatophagoides Pteronyssinus immunotherapy:

  • Reduction in allergy symptoms: Patients often experience a decrease in symptoms like sneezing, nasal congestion, and itchy eyes[1].
  • Improved quality of life: As symptoms improve, patients often report a better overall quality of life[2].
  • Long-term benefits: Unlike medications that only provide temporary relief, immunotherapy can offer long-lasting benefits, even after the treatment is completed.

However, it’s important to note that the effectiveness can vary from person to person, and it may take several months to a year to see significant improvements.

Side Effects and Safety

While Dermatophagoides Pteronyssinus immunotherapy is generally considered safe, it can cause some side effects:

  • Local reactions: Redness, swelling, or itching at the injection site (for SCIT)[3].
  • Systemic reactions: In rare cases, more severe allergic reactions can occur, which is why the treatment is administered under medical supervision[3].

Safety measures are always in place during treatment, and patients are typically monitored for a period after each dose to ensure no adverse reactions occur.

Current Clinical Trials

Ongoing research continues to explore the potential of Dermatophagoides Pteronyssinus immunotherapy:

  • Studies are investigating the optimal dosing strategies to maximize effectiveness while minimizing side effects[3].
  • Researchers are examining the long-term effects of immunotherapy on allergic rhinitis and asthma prevention[1].
  • New methods of administration, such as nasal sprays, are being evaluated for their efficacy and patient convenience[2].

These ongoing trials aim to improve our understanding of how to best use Dermatophagoides Pteronyssinus extract to help patients with dust mite allergies.

Aspect Details
Study Focus Evaluation of Dermatophagoides Pteronyssinus extract for allergic rhinitis treatment
Main Objectives Assess safety, efficacy, immune responses, diagnostic methods, and compare treatment regimens
Treatment Method Allergen-specific immunotherapy with gradually increasing doses
Outcome Measures Symptom scores, medication use, quality of life, immunological markers, nasal provocation tests
Safety Monitoring Local and systemic adverse events, vital signs, physical examinations
Study Designs Randomized, double-blind, placebo-controlled trials with various dosing regimens
Patient Population Individuals with allergic rhinitis sensitized to house dust mites
Duration Varying from 1 to 3 years, depending on the specific trial

Ongoing Clinical Trials on Dermatophagoides Pteronyssinus

  • Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

    Recruiting

    Investigated diseases:
    Spain
  • Study on the Safety and Effectiveness of Subcutaneous Immunotherapy with Der p 1, Der p 2, and Der p 23 Allergens for Patients with Allergic Rhinitis or Rhinoconjunctivitis

    Recruiting

    Investigated diseases:
    Spain
  • Study on the Effectiveness of Dermatophagoides Allergen Extracts for Allergy Patients Using Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Solutions

    Not yet recruiting

    1 1
    Investigated diseases:
    Spain
  • Study on the Effectiveness of Dermatophagoides Allergen Extracts and Histamine Dihydrochloride for Patients with Allergies

    Not recruiting

    1 1
    Investigated diseases:
    Spain
  • Study on Allergenic Extracts of Mites and Histamine Dihydrochloride for Allergy Patients

    Not recruiting

    1 1
    Investigated diseases:
    Spain
  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    1 1 1
    Austria Bulgaria Germany Latvia Lithuania Poland
  • Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

    Not recruiting

    1 1 1
    Germany

Glossary

  • Allergic Rhinitis: An allergic inflammation of the nasal airways, characterized by symptoms such as sneezing, nasal congestion, runny nose, and itching, typically triggered by allergens like house dust mites.
  • Dermatophagoides Pteronyssinus: A species of house dust mite that is a common cause of allergic reactions in humans, particularly associated with allergic rhinitis and asthma.
  • Allergen-Specific Immunotherapy (SIT): A treatment method for allergies that involves administering gradually increasing doses of an allergen to reduce sensitivity and alleviate symptoms over time.
  • Regulatory T Cells (Treg): A type of immune cell that plays a crucial role in maintaining immune system balance and preventing autoimmune diseases. They are important in the mechanism of allergen immunotherapy.
  • Nasal Provocation Test (NPT): A diagnostic procedure where an allergen is applied directly to the nasal mucosa to evaluate the presence and severity of an allergic reaction.
  • Total 5 Symptom Score (T5SS): A scoring system used to assess the severity of allergic rhinitis symptoms, including rhinorrhea, sneezing, nasal congestion, and nasal and ocular pruritus.
  • Combined Symptom and Medication Score (CSMS): A scoring system that combines symptom severity and medication use to evaluate the overall impact of allergic rhinitis and the effectiveness of treatments.
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ): A standardized questionnaire used to assess the impact of allergic rhinitis on a patient's quality of life across various domains.
  • Protein Activity Units (PAU): A measure of the allergenic activity in immunotherapy extracts, used to standardize dosing across different preparations.

References

  1. https://clinicaltrials.gov/study/NCT01291381
  2. https://clinicaltrials.gov/study/NCT04915352
  3. https://clinicaltrials.gov/study/NCT05525650